Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer Lipitor Profitability Among Items In Dispute In Warner-Lambert Bid

  • News

Executive Summary

The effect of the Lipitor co-promotion on Pfizer's earnings ranges from break-even to one quarter of profits, depending on which partner in the agreement is doing the accounting.

You may also be interested in...



Pfizer/Warner Pro Forma Accounting Shows 1.5% Margin Benefit From Lipitor

Pfizer/Warner-Lambert's pro forma operating margins will be 1.5 percentage points closer to the Pfizer level after the elimination of double-counting of Lipitor sales.

Pfizer/Warner Pro Forma Accounting Shows 1.5% Margin Benefit From Lipitor

Pfizer/Warner-Lambert's pro forma operating margins will be 1.5 percentage points closer to the Pfizer level after the elimination of double-counting of Lipitor sales.

Pfizer/Warner-Lambert Savings Would Be Akin To Acquiring Another Zoloft

A Pfizer/Warner-Lambert combination would achieve $1.6 bil. in cost savings by 2002, Pfizer declared.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS035209

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By